Literature DB >> 23035230

Genetic subpopulations of Rift Valley fever virus strains ZH548 and MP-12 and recombinant MP-12 strains.

Nandadeva Lokugamage1, Alexander N Freiberg, John C Morrill, Tetsuro Ikegami.   

Abstract

Rift Valley fever virus strain MP-12 was generated by serial plaque passages of parental strain ZH548 12 times in MRC-5 cells in the presence of a chemical mutagen, 5-fluorouracil. As a result, MP-12 encoded 4, 9, and 10 mutations in the S, M, and L segments, respectively. Among them, mutations in the M and L segments were responsible for attenuation, while the MP-12 S segment still encoded a virulent phenotype. We performed high-throughput sequencing of MP-12 vaccine, ZH548, and recombinant MP-12 (rMP-12) viruses. We found that rMP-12 contains very low numbers of viral subpopulations, while MP-12 and ZH548 contain 2 to 4 times more viral genetic subpopulations than rMP-12. MP-12 genetic subpopulations did not encode the ZH548 sequence at the 23 MP-12 consensus mutations. On the other hand, 4 and 2 mutations in M and L segments of MP-12 were found in ZH548 subpopulations. Thus, those 6 mutations were no longer MP-12-specific mutations. ZH548 encoded several unique mutations compared to other Egyptian strains, i.e., strains ZH501, ZH1776, and ZS6365. ZH548 subpopulations shared nucleotides at the mutation site common with those in the Egyptian strains, while MP-12 subpopulations did not share those nucleotides. Thus, MP-12 retains unique genetic subpopulations and has no evidence of reversion to the ZH548 sequence in the subpopulations. This study provides the first information regarding the genetic subpopulations of RVFV and shows the genetic stability of the MP-12 vaccine manufactured in MRC-5 cells.

Entities:  

Mesh:

Year:  2012        PMID: 23035230      PMCID: PMC3503115          DOI: 10.1128/JVI.02081-12

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  31 in total

Review 1.  RNA editing by adenosine deaminases that act on RNA.

Authors:  Brenda L Bass
Journal:  Annu Rev Biochem       Date:  2001-11-09       Impact factor: 23.643

2.  Rift Valley fever virus (family Bunyaviridae, genus Phlebovirus). Isolations from Diptera collected during an inter-epizootic period in Kenya.

Authors:  K J Linthicum; F G Davies; A Kairo; C L Bailey
Journal:  J Hyg (Lond)       Date:  1985-08

3.  Mutagen-directed attenuation of Rift Valley fever virus as a method for vaccine development.

Authors:  H Caplen; C J Peters; D H Bishop
Journal:  J Gen Virol       Date:  1985-10       Impact factor: 3.891

4.  A Rift Valley fever vaccine trial: 2. Serological response to booster doses with a comparison of intradermal versus subcutaneous injection.

Authors:  J D Kark; Y Aynor; C J Peters
Journal:  Vaccine       Date:  1985-06       Impact factor: 3.641

5.  The Rift Valley fever epizootic in Egypt 1977-78. 1. Description of the epizzotic and virological studies.

Authors:  J M Meegan
Journal:  Trans R Soc Trop Med Hyg       Date:  1979       Impact factor: 2.184

6.  TFIIH transcription factor, a target for the Rift Valley hemorrhagic fever virus.

Authors:  Nicolas Le May; Sandy Dubaele; Luca Proietti De Santis; Agnès Billecocq; Michèle Bouloy; Jean-Marc Egly
Journal:  Cell       Date:  2004-02-20       Impact factor: 41.582

7.  Molecular epidemiology of Rift Valley fever virus.

Authors:  Antoinette A Grobbelaar; Jacqueline Weyer; Patricia A Leman; Alan Kemp; Janusz T Paweska; Robert Swanepoel
Journal:  Emerg Infect Dis       Date:  2011-12       Impact factor: 6.883

8.  The Rift Valley Fever virus protein NSm and putative cellular protein interactions.

Authors:  Cecilia Engdahl; Jonas Näslund; Lena Lindgren; Clas Ahlm; Göran Bucht
Journal:  Virol J       Date:  2012-07-28       Impact factor: 4.099

9.  Infection and transmission of Rift Valley fever viruses lacking the NSs and/or NSm genes in mosquitoes: potential role for NSm in mosquito infection.

Authors:  Mary B Crabtree; Rebekah J Kent Crockett; Brian H Bird; Stuart T Nichol; Bobbie Rae Erickson; Brad J Biggerstaff; Kalanthe Horiuchi; Barry R Miller
Journal:  PLoS Negl Trop Dis       Date:  2012-05-01

Review 10.  Adenosine deaminases acting on RNA (ADARs): RNA-editing enzymes.

Authors:  Liam P Keegan; Anne Leroy; Duncan Sproul; Mary A O'Connell
Journal:  Genome Biol       Date:  2004-02-02       Impact factor: 13.583

View more
  16 in total

1.  Immunogenicity of a recombinant Rift Valley fever MP-12-NSm deletion vaccine candidate in calves.

Authors:  John C Morrill; Richard C Laughlin; Nandadeva Lokugamage; Jing Wu; Roberta Pugh; Pooja Kanani; L Garry Adams; Shinji Makino; C J Peters
Journal:  Vaccine       Date:  2013-08-27       Impact factor: 3.641

Review 2.  Rift Valley fever vaccines: an overview of the safety and efficacy of the live-attenuated MP-12 vaccine candidate.

Authors:  Tetsuro Ikegami
Journal:  Expert Rev Vaccines       Date:  2017-05-02       Impact factor: 5.217

3.  Rift Valley Fever Virus MP-12 Vaccine Is Fully Attenuated by a Combination of Partial Attenuations in the S, M, and L Segments.

Authors:  Tetsuro Ikegami; Terence E Hill; Jennifer K Smith; Lihong Zhang; Terry L Juelich; Bin Gong; Olga A L Slack; Hoai J Ly; Nandadeva Lokugamage; Alexander N Freiberg
Journal:  J Virol       Date:  2015-05-06       Impact factor: 5.103

Review 4.  Single-cycle replicable Rift Valley fever virus mutants as safe vaccine candidates.

Authors:  Kaori Terasaki; Breanna R Tercero; Shinji Makino
Journal:  Virus Res       Date:  2015-05-27       Impact factor: 3.303

5.  Impact of Protein Glycosylation on the Design of Viral Vaccines.

Authors:  Kathleen Schön; Bernd Lepenies; Guillaume Goyette-Desjardins
Journal:  Adv Biochem Eng Biotechnol       Date:  2021       Impact factor: 2.635

6.  Cytokine response in mouse bone marrow derived macrophages after infection with pathogenic and non-pathogenic Rift Valley fever virus.

Authors:  Kimberly K Roberts; Terence E Hill; Melissa N Davis; Michael R Holbrook; Alexander N Freiberg
Journal:  J Gen Virol       Date:  2015-03-10       Impact factor: 3.891

7.  Countermeasure development for Rift Valley fever: deletion, modification or targeting of major virulence factor NSs.

Authors:  Olga Lihoradova; Tetsuro Ikegami
Journal:  Future Virol       Date:  2014-01-01       Impact factor: 1.831

8.  Rift Valley fever MP-12 vaccine Phase 2 clinical trial: Safety, immunogenicity, and genetic characterization of virus isolates.

Authors:  Phillip R Pittman; Sarah L Norris; Elizabeth S Brown; Manmohan V Ranadive; Barbara A Schibly; George E Bettinger; Nandadeva Lokugamage; Lawrence Korman; John C Morrill; Clarence J Peters
Journal:  Vaccine       Date:  2015-12-17       Impact factor: 3.641

9.  The L, M, and S Segments of Rift Valley Fever Virus MP-12 Vaccine Independently Contribute to a Temperature-Sensitive Phenotype.

Authors:  Shoko Nishiyama; Nandadeva Lokugamage; Tetsuro Ikegami
Journal:  J Virol       Date:  2016-01-27       Impact factor: 5.103

10.  Rift Valley fever virus MP-12 vaccine encoding Toscana virus NSs retains neuroinvasiveness in mice.

Authors:  Sabarish V Indran; Olga A Lihoradova; Inaia Phoenix; Nandadeva Lokugamage; Birte Kalveram; Jennifer A Head; Bersabeh Tigabu; Jennifer K Smith; Lihong Zhang; Terry L Juelich; Bin Gong; Alexander N Freiberg; Tetsuro Ikegami
Journal:  J Gen Virol       Date:  2013-03-20       Impact factor: 3.891

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.